PALEKAR ROHAN
Insider CIK 1423327 · NLTX Director · ETNB Chief Executive Officer, Director · AVNR SVP & Chief Commercial Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| NGNE Neurogene Inc. | A Award deriv | 2026-02-20 | 2026-02-24 | 12,050 | — | $0 | 12,050 | SEC↗ |
| ETNB 89bio, Inc. | D To issuer deriv | 2025-10-30 | 2025-10-30 | 170,000 | — | $0 | 0 | SEC↗ |
| ETNB 89bio, Inc. | D To issuer deriv | 2025-10-30 | 2025-10-30 | 203,750 | — | $0 | 0 | SEC↗ |
| ETNB 89bio, Inc. | D To issuer deriv | 2025-10-30 | 2025-10-30 | 220,000 | — | $0 | 0 | SEC↗ |
| ETNB 89bio, Inc. | D To issuer deriv | 2025-10-30 | 2025-10-30 | 120,231 | — | $0 | 0 | SEC↗ |
| ETNB 89bio, Inc. | D To issuer deriv | 2025-10-30 | 2025-10-30 | 132,242 | — | $0 | 0 | SEC↗ |
| ETNB 89bio, Inc. | D To issuer deriv | 2025-10-30 | 2025-10-30 | 848,000 | — | $0 | 0 | SEC↗ |
| ETNB 89bio, Inc. | D To issuer deriv | 2025-10-30 | 2025-10-30 | 605,000 | — | $0 | 0 | SEC↗ |
| ETNB 89bio, Inc. | D To issuer deriv | 2025-10-30 | 2025-10-30 | 300,000 | — | $0 | 0 | SEC↗ |
| ETNB 89bio, Inc. | A Award | 2025-10-30 | 2025-10-30 | 125,000 | — | $0 | 934,273 | SEC↗ |
| ETNB 89bio, Inc. | U Tender | 2025-10-30 | 2025-10-30 | 934,273 | — | $0 | 0 | SEC↗ |
| ETNB 89bio, Inc. | F Tax w/h | 2025-08-01 | 2025-08-05 | 55,836 | $9.16 | $511.5K | 808,070 | SEC↗ |
| NGNE Neurogene Inc. | A Award deriv | 2025-06-12 | 2025-06-13 | 12,050 | — | $0 | 12,050 | SEC↗ |
| ETNB 89bio, Inc. | F Tax w/h | 2025-02-17 | 2025-02-19 | 3,249 | $10.57 | $34.3K | 862,240 | SEC↗ |
| ETNB 89bio, Inc. | F Tax w/h | 2025-02-09 | 2025-02-11 | 8,946 | $11.41 | $102.1K | 864,692 | SEC↗ |
| ETNB 89bio, Inc. | A Award deriv | 2025-02-01 | 2025-02-04 | 848,000 | — | $0 | 848,000 | SEC↗ |
| ETNB 89bio, Inc. | A Award | 2025-02-01 | 2025-02-04 | 200,000 | — | $0 | 883,236 | SEC↗ |
| ETNB 89bio, Inc. | F Tax w/h | 2025-02-01 | 2025-02-04 | 9,598 | $9.60 | $92.1K | 873,638 | SEC↗ |
| ETNB 89bio, Inc. | A Award | 2025-02-01 | 2025-02-04 | 212,000 | — | $0 | 683,236 | SEC↗ |
| ETNB 89bio, Inc. | P Buy | 2024-12-06 | 2024-12-10 | 5,000 | $7.89 | $39.5K | 471,236 | SEC↗ |
| ETNB 89bio, Inc. | P Buy | 2024-11-22 | 2024-11-25 | 10,000 | $8.35 | $83.5K | 466,236 | SEC↗ |
| ETNB 89bio, Inc. | F Tax w/h | 2024-08-17 | 2024-08-19 | 4,601 | $8.04 | $37.0K | 456,236 | SEC↗ |
| NGNE Neurogene Inc. | A Award deriv | 2024-06-14 | 2024-06-17 | 7,700 | — | $0 | 7,700 | SEC↗ |
| ETNB 89bio, Inc. | M Exercise deriv | 2024-04-01 | 2024-04-03 | 25,000 | — | $0 | 120,231 | SEC↗ |
| ETNB 89bio, Inc. | M Exercise | 2024-04-01 | 2024-04-03 | 25,000 | $1.93 | $48.3K | 511,889 | SEC↗ |
| ETNB 89bio, Inc. | S Sale | 2024-04-01 | 2024-04-03 | 52,718 | $10.91 | $575.2K | 459,171 | SEC↗ |
| ETNB 89bio, Inc. | S Sale | 2024-02-26 | 2024-02-28 | 4,477 | $10.76 | $48.2K | 486,889 | SEC↗ |
| ETNB 89bio, Inc. | F Tax w/h | 2024-02-17 | 2024-02-23 | 4,602 | $9.74 | $44.8K | 491,366 | SEC↗ |
| ETNB 89bio, Inc. | F Tax w/h | 2024-02-09 | 2024-02-13 | 12,670 | $8.45 | $107.1K | 480,968 | SEC↗ |
| ETNB 89bio, Inc. | F Tax w/h | 2024-02-05 | 2024-02-05 | 5,068 | $9.80 | $49.7K | 493,646 | SEC↗ |
| ETNB 89bio, Inc. | A Award deriv | 2024-02-01 | 2024-02-05 | 605,000 | — | $0 | 605,000 | SEC↗ |
| ETNB 89bio, Inc. | A Award | 2024-02-01 | 2024-02-05 | 150,000 | — | $0 | 498,714 | SEC↗ |
| NGNE Neurogene Inc. | A Award deriv | 2024-01-16 | 2024-01-18 | 15,400 | — | $0 | 15,400 | SEC↗ |
| ETNB 89bio, Inc. | A Award | 2024-01-05 | 2024-01-08 | 75,000 | — | $0 | 376,225 | SEC↗ |
| ETNB 89bio, Inc. | F Tax w/h | 2024-01-05 | 2024-01-08 | 27,511 | $11.53 | $317.2K | 348,714 | SEC↗ |
| ETNB 89bio, Inc. | M Exercise deriv | 2023-12-29 | 2024-01-03 | 50,000 | — | $0 | 145,231 | SEC↗ |
| ETNB 89bio, Inc. | M Exercise | 2023-12-29 | 2024-01-03 | 50,000 | $1.93 | $96.5K | 351,225 | SEC↗ |
| ETNB 89bio, Inc. | S Sale | 2023-12-29 | 2024-01-03 | 50,000 | $11.20 | $560.0K | 301,225 | SEC↗ |
| ETNB 89bio, Inc. | F Tax w/h | 2023-08-17 | 2023-08-21 | 4,501 | $15.46 | $69.6K | 300,950 | SEC↗ |
| ETNB 89bio, Inc. | A Award | 2023-06-30 | 2023-07-05 | 33,334 | — | $0 | 321,978 | SEC↗ |
| ETNB 89bio, Inc. | F Tax w/h | 2023-06-30 | 2023-07-05 | 16,527 | $18.95 | $313.2K | 305,451 | SEC↗ |
| NLTX Neoleukin Therapeutics, In | A Award deriv | 2023-06-08 | 2023-06-09 | 25,000 | — | $0 | 25,000 | SEC↗ |
| ETNB 89bio, Inc. | M Exercise deriv | 2023-06-05 | 2023-06-07 | 15,000 | — | $0 | 195,231 | SEC↗ |
| ETNB 89bio, Inc. | S Sale | 2023-06-05 | 2023-06-07 | 15,000 | $20.00 | $300.0K | 286,978 | SEC↗ |
| ETNB 89bio, Inc. | M Exercise | 2023-06-05 | 2023-06-07 | 15,000 | $1.93 | $28.9K | 301,978 | SEC↗ |
| ETNB 89bio, Inc. | A Award | 2023-03-31 | 2023-04-04 | 33,333 | — | $0 | 302,413 | SEC↗ |
| ETNB 89bio, Inc. | F Tax w/h | 2023-03-31 | 2023-04-04 | 15,443 | $15.23 | $235.2K | 286,970 | SEC↗ |
| ETNB 89bio, Inc. | S Sale | 2023-03-23 | 2023-03-27 | 15,000 | $16.00 | $240.0K | 269,080 | SEC↗ |
| ETNB 89bio, Inc. | F Tax w/h | 2023-02-17 | 2023-02-22 | 6,279 | $13.97 | $87.7K | 284,072 | SEC↗ |
| ETNB 89bio, Inc. | A Award deriv | 2023-02-09 | 2023-02-13 | 300,000 | — | $0 | 300,000 | SEC↗ |
| ETNB 89bio, Inc. | A Award | 2023-02-09 | 2023-02-13 | 75,000 | — | $0 | 290,351 | SEC↗ |
| ETNB 89bio, Inc. | F Tax w/h | 2023-02-05 | 2023-02-07 | 4,078 | $13.24 | $54.0K | 215,351 | SEC↗ |
| ETNB 89bio, Inc. | F Tax w/h | 2022-09-28 | 2022-09-30 | 11,527 | $5.76 | $66.4K | 219,429 | SEC↗ |
| ETNB 89bio, Inc. | A Award | 2022-09-28 | 2022-09-30 | 33,333 | — | $0 | 230,956 | SEC↗ |
| ETNB 89bio, Inc. | M Exercise deriv | 2022-09-08 | 2022-09-09 | 100,000 | — | $0 | 225,231 | SEC↗ |
| ETNB 89bio, Inc. | M Exercise | 2022-09-08 | 2022-09-09 | 100,000 | $1.93 | $193.0K | 197,623 | SEC↗ |
| NLTX Neoleukin Therapeutics, In | A Award deriv | 2022-05-12 | 2022-05-16 | 25,000 | — | $0 | 25,000 | SEC↗ |
| NLTX Neoleukin Therapeutics, In | A Award deriv | 2022-03-02 | 2022-03-04 | 50,000 | — | $0 | 50,000 | SEC↗ |
| ETNB 89bio, Inc. | A Award deriv | 2022-02-17 | 2022-02-22 | 220,000 | — | $0 | 220,000 | SEC↗ |
| ETNB 89bio, Inc. | A Award | 2022-02-17 | 2022-02-22 | 54,200 | — | $0 | 100,045 | SEC↗ |
| ETNB 89bio, Inc. | F Tax w/h | 2022-02-05 | 2022-04-13 | 4,088 | $5.23 | $21.4K | 95,957 | SEC↗ |
| ETNB 89bio, Inc. | P Buy | 2022-01-28 | 2022-01-31 | 2,500 | $6.14 | $15.3K | 45,845 | SEC↗ |
| ETNB 89bio, Inc. | P Buy | 2022-01-27 | 2022-01-31 | 5,000 | $7.50 | $37.5K | 43,345 | SEC↗ |
| ETNB 89bio, Inc. | P Buy | 2021-07-08 | 2021-07-08 | 2,000 | $16.25 | $32.5K | 37,000 | SEC↗ |
| ETNB 89bio, Inc. | P Buy | 2021-07-07 | 2021-07-08 | 5,000 | $17.07 | $85.3K | 35,000 | SEC↗ |
| ETNB 89bio, Inc. | A Award deriv | 2021-02-05 | 2021-02-09 | 203,750 | — | $0 | 203,750 | SEC↗ |
| ETNB 89bio, Inc. | A Award | 2021-02-05 | 2021-02-09 | 30,000 | — | $0 | 30,000 | SEC↗ |
| ETNB 89bio, Inc. | A Award deriv | 2020-02-14 | 2020-02-19 | 170,000 | — | $0 | 170,000 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | M Exercise deriv | 2014-11-28 | 2014-11-28 | 15,000 | — | $0 | 235,000 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | S Sale | 2014-11-28 | 2014-11-28 | 15,000 | $15.00 | $225.0K | 302,806 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | A Award | 2014-11-10 | 2014-11-12 | 59,231 | — | $0 | 282,981 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | A Award | 2014-11-10 | 2014-11-12 | 34,825 | — | $0 | 317,806 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | M Exercise deriv | 2014-09-15 | 2014-09-17 | 25,000 | — | $0 | 250,000 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | S Sale | 2014-09-15 | 2014-09-17 | 10,000 | $10.00 | $100.0K | 266,750 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | S Sale | 2014-09-15 | 2014-09-17 | 15,000 | $12.50 | $187.5K | 266,750 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | A Award | 2014-02-12 | 2014-02-14 | 80,750 | — | $0 | 223,750 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | A Award | 2014-02-12 | 2014-02-14 | 43,000 | — | $0 | 266,750 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | P Buy | 2013-12-17 | 2013-12-19 | 10,000 | $2.80 | $28.0K | 143,000 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | A Award deriv | 2013-12-13 | 2013-12-17 | 47,500 | — | $0 | 47,500 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | P Buy | 2013-11-04 | 2013-11-05 | 10,000 | $4.19 | $41.9K | 133,000 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | A Award deriv | 2012-12-17 | 2012-12-19 | 56,250 | — | $0 | 56,250 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | A Award | 2012-12-17 | 2012-12-19 | 36,844 | — | $0 | 96,844 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | A Award | 2012-12-17 | 2012-12-19 | 26,156 | — | $0 | 123,000 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | P Buy | 2012-12-13 | 2012-12-17 | 10,000 | $2.46 | $24.6K | 60,000 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | A Award deriv | 2012-04-03 | 2012-11-02 | 275,000 | — | $0 | 275,000 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | A Award | 2012-04-03 | 2012-11-02 | 30,000 | — | $0 | 50,000 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | A Award | 2012-04-03 | 2012-11-02 | 20,000 | — | $0 | 20,000 | SEC↗ |